Target-controlled infusion of propofol and remifentanil combined with dexmedetomidine reduces functional endoscopic sinus surgery bleeding

• Published in: Experimental and therapeutic medicine Vol. 14; no. 5; pp. 4521 - 4526
• Main Authors: Ding, Deng-Feng, Wu, Li-Fang, Wang, Ping, Jiang, Yuan-Xu, Luo, Yao-Wen, Dai, Zhong-Liang, Zhang, Xue-Ping, Li, Ya-Li
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.11.2017; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Anesthesia; Body mass index; Cardiovascular disease; Complications and side effects; Data collection; Dexmedetomidine; Dosage and administration; Drugs; Endoscopy; functional endoscopic sinus surgery; Hemorrhage; Intubation; Medical personnel; Patients; Prevention; Propofol; Remifentanil; Risk factors; Sinuses; Standard deviation; Studies; Surgeons; Surgery; China; dexmedetomidine; remifentanil; propofol; functional endoscopic sinus surgery
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2017.5075

The aim of the present study was to investigate the effects of target-controlled infusion (TCI) of propofol and remifentanil combined with dexmedetomidine on functional endoscopic sinus surgery (FESS) bleeding and surgical field. 62 patients scheduled to undergo FESS were randomly divided into experimental group (intravenous 0.5 µg kg−1 h−1 dexmedetomidine after 0.5 µg kg−1 bolus within 15 min until the end of surgery) or control group (intravenous saline administration at the same dose). All patients underwent endotracheal intubation under general anesthesia with TCI of propofol and remifentanil for anesthesia induction and maintenance. During anesthesia, arterial pressure (MAP), heart rate (HR), intraoperative propofol and remifentanil dosage and intraoperative blood loss were recorded. Surgeons rated their satisfaction with the surgical field using the Numeric Rating Scale (NRS). Following surgery, visual analog scale (VAS) was assessed. During tracheal intubation and extubation, HR and MAP in the experimental group were significantly lower compared with the control group (P<0.05); HR was also significantly lower compared with the control group throughout surgery (P<0.05). The mean infusion rate of propofol and remifentanil was significantly lower in the experimental group compared with the control group (P=0.001 and P=0.045, respectively). Blood loss in the experimental group was significantly lower compared with the control group (P=0.007). NRS and VAS scores in the experimental group were significantly improved compared with control group (P<0.01). In conclusion, TCI of propofol and remifentanil for FESS combined with dexmedetomidine reduced intraoperative bleeding and improved the quality of surgical field compared with the same procedure without dexmedetomidine. Dexmedetomidine also reduced the increase in MAP and HR during tracheal intubation and extubation, and improved postoperative analgesia quality.